camptothecin.
The (Hansen, 1992) . This knowledge suggests that we do not need new drugs with effect on the sensitive cells, but drugs active on the resistant cells at relapse. The epipodophyllotoxin VP-16 is one of the most effective drugs when used as a single agent (Bork et al., 1991) , and it is the most frequently used drug in SCLC protocols (Kristjansen & Hirsch, 1989) . Thus, VP-16 will undoubtedly be widely used in future protocols and mechanisms of resistance to this important drug are therefore of special interest. Experimental resistance to VP-16 always seems to include multidrug resistance (MDR) with cross-resistance to other chemically unrelated drugs (Ferguson et al., 1988; Long et al., 1991; Sehested et al., 1992) . Two well defined mechanisms of MDR have been identified:
The first is reduction of the intracellular drug accumulation (Dan0, 1973; Skovsgaard, 1978) due to P-glycoprotein in the plasma membrane, also called classical MDR (reviewed in (Endicott & Ling, 1989) ). The second mechanism is altered or reduced topoisomerase II activity reducing the target sensitivity to most anthracyclines and epipodophyllotoxins (at-MDR) (Danks et al., 1988) . In SCLC both classical P-glycoprotein MDR lines (Reeve et al., 1989; Minato et al., 1990; Jensen et al., 1989b; Vries, E.G.E. et al., 1989) and at-MDR (de Jong et al., 1990; Jensen et al., 1991b) cells have been described. In addition to these well defined mechanisms of MDR, there are reports describing VP-16 and vincristine cross-resistance in MDR SCLC cells without P-glycoprotein. This was found in the MDR H69AT cell line by Cole et al. (1991) . Drug accumulation was apparently not reduced in H69AT, whereas a reduction in drug accumulation was described by Versantvoort et al. (1992) in their MDR cell line GLC4. H69/VP developed in our laboratory belongs to this last phenotype as it is P-glycoprotein negative, it is resistant to VP-16 and vincristine and, as shown in the present report, it exhibits a reduced drug accumulation. Similar data have been obtained in NSCLC cell lines and alternative drug efflux proteins or alternative mechanisms of MDR have been suggested (Cole, 1992; Coley et al., 1991; Versantvoort et al., 1992) . Such alternative mechanisms of MDR may be of particular importance in lung cancer as P-glycoprotein appears to be relatively seldom overexpressed in lung cancer biopsies (Nooter & Herweijer, 1991 Franco et al. (1984) . To our surprise, however, vinblastine was found to be unstable and was therefore not included in the study.
Cell lines
The human SCLC cell lines used were, NCI-H69 (Carney et al., 1985) , NCI-N592 (Carney et al., 1985) , OC-NYH (de Leij et al., 1985) , OC-TOL (de Leij et al., 1985) , GLC-16 (Berendsen et al., 1988) , and SCLC 86-Ml (Bepler et al., 1987) . the multidrug resistant (MDR) SCLC cell lines used were NCI-H69/DAU4, NCI-H69/VP, and OC-NYH/VM selected for resistance to daunorubicin, VP-16, and VM-26 respectively. NCI-H69/DAU4 is a classical MDR cell line with Pglycoprotein in the cell membrane (Jensen et al., 1989b) , OC-NYH/VM is resistant due to altered topoisomerase II activity (Jensen et al., 1991b) , and NCI-H69/VP is resistant to vincristine as NCI-H69/DAU4, but is without P-glycoprotein expression and the mechanism(s) responsible for resistance in this line is still under investigation . Resistant cell lines were grown in vitro without drug for a minimum of 5 days before testing. All cell lines were maintained at 37°C in RPMI 1640 with 10% foetal calf serum in a humidified atmosphere with 7.5% CO2. At regular intervals the panel of cell lines was re-established from frozen sub-cultures to reduce or avoid sensitivity drifting. The cell lines were free of mycoplasm contamination DNA content (Vindel0v & Christensen, 1990) , plating efficiency, relation to chemotherapy, and growth behaviour in vitro of the cell lines used are described in Table I . Also, Table I shows the relative resistance of H69/DAU4, H69/VP, and NYH/VM to doxorubicin (DOX), vincristine (VCR) and VP-16.
Determination of 3H-daunorubicin accumulation This was performed as described by Skovsgaard (1978) with the modification that the SCLC cells in single cell suspensions were incubated for 15 min with DNase I (0.025% w/v) (Sigma) before being exposed to daunorubicin (Versantvoort et al., 1992 (Skovsgaard, 1978 (Jensen et al., 1989a) . In our attempts to rationalize 'in vitro phase II trials in SCLC' the task was therefore to obtain more dose-response curves on one batch of cells. Since manual colony counting would be prohibitively laborious, we developed an automatic colony counter consisting of a videocamera built around a SB1024 image processing board (Bio-Rad Scan-Beam, Hadsund, Denmark) equipped with a motor steering for counting of 18 dishes. This enabled the automatic counting of colonies in 200 Petri dishes a day, with minimal expenditure of labour. In the experiments, single-cell suspensions (1-4 x 104 cells ml-') in RPMI 1640 supplemented with 10% foetal calf serum were plated in soft agar on a feeder layer containing sheep red blood cells (Roed et al., 1987) in 35 mm petri dishes with the desired drug concentrations (continuous incubation). The number of cells were adjusted to obtain 2000-3000 colonies in the control dishes. In each experiment all 19 drugs (three concentrations of each, all plated in triplicate) and six control triplicates were tested on the same batch of cells. Solvent concentrations never exceeded 1% and had no influence on the plating efficiency. Plating was effectuated within one hour as the intraexperimental variation in plating efficiency of the controls exceeded 10% in more prolonged experiments. After 14-21 days the colonies were counted on the image analysis system. Colonies larger than 5011M in diameter were regarded as positive. The colony counter was interfaced with an IBM PS-2 60 computer and data was stored and analysed through use of SAS software. The dose reducing the number of colonies to 50% of control (LD50) was determined from three drug concentration points in linear regression analysis on logarithmically transformed response-data (Jensen et al., 1989a) . The drug concentrations chosen approximated to LD1O, LD50, and LD90 obtained on cell line OC-NYH from dose-response curves in previous experiments and were as follows (gM): BCNU (2.3; 7.0; 14) When the calculated LD50 values were above 3 x the highest tested concentration, the LD50 was assigned this value (i.e. 3 x LD90 on OC-NYH). Such 'horizontal' dose-response curves were only observed with some of the 'MDR' drugs in the resistant lines and accordingly their precise relative resistance is not defined. The relative resistance obtained in previous experiments with properly adjusted doses are shown in Table I . Patterns in sensitivity were studied by correlation analysis using rank orders of sensitivity with all possible pairings of the 19 agents. LD50 values from two experiments on each cell line were included in the analysis. Computations utilised correlation coefficients calculated as Spearman rank order correlations. Daunorubicin accumulation in the three different MDR cell lines We have previously shown that NCI-H69/DAU4 expresses P-glycoprotein (Jensen et al., 1989b) , whereas the protein is not detectable in the resistant sublines NCI-H69/VP and OC-NYH/VM . The cell line OC-NYH/ VM has the characteristics of an at-MDR phenotype (Danks et al., 1988) , whereas NCI-H69/VP is cross-resistant to vincristine and the resistance mechanism(s) in this cell line is still there is a 3-fold increase in daunorubicin accumulation almost reaching a 'wild type' level. If energy production is restored as seen by the effect of addition of glucose to the azide incubations the drug accumulation is reduced. This effect is similar to the results obtained by Dan0 (1973) on the classic P-glycoprotein expressing MDR Ehrlich ascites tumour cells. As expected, verapamil which is a modulator of P-glycoprotein mediated resistance is also able to increase the drug accumulation in H69/DAU4. A similar pattern is observed in the P-glycoprotein negative H69/VP with a 2-fold increase in drug content when the cells are incubated with azide and a significant reduction by addition of glucose. Thus, in both MDR sublines of H69 one explanation of the resistance is a reduced drug accumulation. In contrast, there is no difference in daunorubicin accumulation in OC-NYH and OC-NYH/VM (Table III) although the latter is four fold less sensitive to daunorubicin (Jensen et al., 1991b) , confirming that this cell line fits the at-MDR phenotype (Danks et al., 1988 correlation coefficients (89%, 99%, and 89% respectively).
The sensitivity pattern to VP-16 is highly correlated to the pattern to doxorubicin (92%), and the drug also exhibits high correlation coefficients to the other topoisomerase TI targeting agents mitoxantrone (81%) and m-AMSA (72%). (Table IV-A) but also in the six 'wild types' (Table IV-B) . In contrast, both Ara-C and camptothecin demonstrate notable reduced correlation coefficients to VP-16 when the MDR lines are included. This reflects the collateral sensitivity exhibited by these compounds in the MDR lines (Figure 1) .
In order to visualise some of the data obtained on the full cell line panel (Table IV -A), the correlations of the 19 drugpatterns to the VP-16 sensitivity pattern were plotted against the corresponding coefficients to BCNU (Figure 3 ). This plot exhibits the remarkable feature of drug-type specific clustering. The topoisomerase II targeting drugs are clustered together, as are the vinca alkaloids, and the lipophilic anthracyclines (iododoxorubicin and aclarubicin). Although more disparate, there also seem to be areas occupied by alkylating agents and pyrimidine antimetabolites (ara-C and 5-FU). In addition, this plot demonstrates that drugs as ara-C and camptothecin exhibit sensitivity patterns that differ both from VP-16 and from the alkylating agents BCNU and cisplatin. Thereby, the differential sensitivity patterns obtained in the cell line panel enable the selection of noncross-resistant drugs.
Discussion
The present study demonstrates that the clonogenic assay used on this panel of SCLC cell lines is capable of displaying both cell-determined and structure-determined differences in the cytotoxicity of the drugs. As such the panel may provide a useful adjunct to other tumour models in the selection of non-cross-resistant anticancer agents and in elucidating mechanisms of action of new drugs. That such patterns in sensitivity may give clues to the mechanism of action was recently described by Bai et al. (1991) (Jensen et al., 1991a) . This is in contrast to other intercalating agents as doxorubicin and mitoxantrone. The fact that there is cross-resistance to these two drugs but not to ACLA in the at-MDR line OC-NYH/ VM (Figure 1c ) strongly supports the idea that the cytotoxicity of ACLA, in contrast to doxorubicin and mitoxantrone, is independent of topoisomerase II activity (Jensen et al., 1991b (Nooter & Herweijer, 1991) . In patients with acute myelocytic leukaemia there is a significantly reduced survival of patients with overexpression of mdrl mRNA in the leukaemia cells (Pirker et al., 1991) . It is still not settled whether the classical P-glycoprotein MDR phenotype is involved in drug resistance in SCLC. P-glycoprotein positive SCLC cell lines have been generated in the laboratory by us and others (Reeve et al., 1989; Minato et al., 1990; Jensen et al., 1989b) , but the protein appears to be rarely expressed in SCLC tumor biopsies (Nooter & Heerweijer, 1991) . Thus, other mechanisms of resistance may be relevant in SCLC. The presence of alternative transportproteins have been suggested by Versantvoort et at. (1992) and Cole et al. (1991) in their experimental MDR SCLC cell lines, and our data on the P-glycoprotein negative H69/VP cell line also suggest a MDR mechanism involving an active drug efflux. Also alterations in topoisomerase II have been described in experimentally resistant SCLC lines (de Jong et al., 1990; Jensen et al., 1991b; Cole et al., 1991) . The lack of data on topoisomerase II activity in patient biopsies still only enables speculations on its clinical relevance. Therefore, we The clonogenic assay is laborious and accordingly a number of alternative, easier assys have been developed for large-scale screening, e.g. MTT and protein assays (Carmichael et al., 1988; Rubinstein et al., 1990) . Instead of using one of these methods we have rationalised the techniques in the clonogenic assay. Cell handling and interexperimental variation was reduced by using continuous drug exposure (Jensen et al., 1989a,b) Carmichael et al. (1988) found lack of correlation between VP-16 and cisplatin sensitivity in 15 'wild type' SCLC cell lines. There are several explanations to this variance in sensitivity patterns. Thus, different cell lines and assays were employed. The MTT assay measures a combination of drug-induced cytotoxicity and inhibition of cell growth (Campling et al., 1991) , whereas the clonogenic assay measures the loss of reproductive potential in single cells. More importantly, however, the end point of the different investigations differ. Campling et al. (1991) , Smit et al. (1992) , and Tsai et al. (1990) correlated in vitro sensitivity data with clinical outcome, whereas our focus is the comparison of drugs. Our attempt has been to select and develop a cell line panel as a model of SCLC tumours reflecting differential sensitivity patterns. Until now, we have concentrated our efforts on the various VP-16 resistant phenotypes. In the clinic, drug resistance is not confined to VP-16 and an ideal cell line panel should probably include cell lines with resistance to all important drug types. Fortunately it appears that our panel does include cell lines with an intrinsic resistance towards alkylating agents e.g. OC-TOL and OC-NYH. In addition, we are in the process of developing cell lines with resistance to both VP-16 and cisplatin.
The value of a drug screening model is ultimately established by its ability to identify combinations of drugs or new compounds which are useful in clinical treatment. In this context it is important that the model reflects experimental and clinical experience. We feel that our model is supported by the following findings:
(1) The clinical synergy between cisplatin and VP-16 in SCLC (Porter et al., 1985) seems to be reflected in our panel by the lack of cross-resistance or even collateral sensitivity between cisplatin and VP-16 (e.g. in H69/ DAU4).
(2) Similarly, our data demonstrate a lack of crossresistance between topoisomerase II targeting agents e.g. mitoxantrone and the antimetabolite ara-C. This combination is widely used in the treatment of acute myelocytic leukaemia. (Cantwell et al., 1988) and new drugs with activity in the doubly resistant cell populations are needed. The sensitivity correlations in Figure 3 and in Table IV -A show that sensitivity patterns to ara-C and camptothecin differ both from topoisomerase II targeting drugs and from alkylating agents, wherefore ara-C and camptothecin appear promising. While ara-C is not clinically active in SCLC, its analogue gemcitabin has demonstrated activity in non-small cell lung cancer (Anderson et al., 1991) . If gemcitabin exhibits a sensitivity pattern identical to ara-C, our data suggests that it could be useful in combination with alkylating agents and 'MDR drugs'. Drugs with effect on the 'new target' topoisomerase I also seem promising. There is no cross-resistance to camptothecin in MDR, indeed, two of our three MDR lines are collaterally sensitive to camptothecin. It is tempting to relate the inverse pattern of sensitivity to the fact that topoisomerase II is able to replace topoisomerase I in vitro (Liu et al., 1989; Yang et al., 1987) . Cells that are resistant to camptothecin appear to depend to a greater extent than wild-type cells upon topoisomerase II activity. This in turn can lead to collateral sensitivity to topoisomerase II targeting agents (Sugimoto et al., 1990) . Such a hypersensitivity was recently described by Mattern et al. (1991) , and we found a similar sensitivity pattern in the human RPM18402/k5 cell line with an altered topoisomerase I (Kjeldsen et al., 1988; Kjeldsen et al., 1991) . Thus, cells resistant to topoisomerase I inhibitors are, in some cases at least, hypersensitive to certain topoisomerase II inhibitors.
In conclusion the present study shows that it is feasible to include 19 drugs in simultaneous experiments in a clonogenic assay. The analysis of the differential cytotoxicity patterns in the panel of cell lines makes it possible (i) to obtain information about drug mechanism of action and enable combinations of non-cross-resistant drugs and (ii) to show where new drugs 'fit in' among established drugs. At present analogues of ara-C and topoisomerase I active drugs appear to be promising as they demonstrate low or negative correlation coefficients both to topoisomerase II targeting agents and to alkylating agents. Annette Nielsen and Eva H0j are thanked for excellent technical assistance, and John Post for preparing the illustrations. Supported by grants from the Danish Cancer Society, the Danish Medical Research Council, and the Lundbeck Foundation.
